How should a pregnant woman with a urinary tract infection be treated if the urine culture grows an ESBL‑producing Enterobacterales?

Treatment of ESBL-Producing UTI in Pregnancy

For pregnant women with ESBL-producing urinary tract infections, carbapenems (ertapenem or meropenem) are the definitive first-line treatment, with IV fosfomycin as an alternative for complicated UTI without septic shock. 1

Treatment Algorithm

Immediate Antibiotic Selection

Parenteral Options (First-Line):

• Carbapenems remain the gold standard for ESBL infections in pregnancy
  • Ertapenem 1g IV daily (preferred for once-daily dosing)
  • Meropenem 1g IV q8h (if severe infection)
  • These maintain near-universal activity against ESBL-producers 2, 3

Alternative Parenteral Options:

• IV Fosfomycin showed non-inferiority to meropenem in the FOREST trial for bacteremic complicated UTI caused by ESBL E. coli 1

  • Critical caveat: 8.6% developed heart failure vs 1% with meropenem
  • Avoid in patients with cardiac risk factors
  • Only use in hemodynamically stable patients without septic shock

• Aminoglycosides (gentamicin, amikacin) for bacteremic UTI of urinary source showed no significant mortality difference vs carbapenems 1

  • Limit duration to ≤7 days due to nephrotoxicity risk 1
  • Particularly important consideration given pregnancy-related physiologic changes

Oral Step-Down or Outpatient Options

When transitioning to oral therapy or treating non-severe cases:

• Fosfomycin (oral): 3g single dose or repeated dosing

  • Resistance rate only 4.9% in community ESBL infections 4
  • Maintained high efficacy in recent surveillance 5, 6

• Nitrofurantoin: 5-day course

  • 99-100% susceptibility maintained 7
  • Avoid after 36 weeks gestation (theoretical neonatal hemolysis risk)

• Pivmecillinam: Where available, effective oral option 8

Avoid These Agents:

• Amoxicillin-clavulanate: Associated with worst outcomes even for susceptible ESBL isolates 4
• Fluoroquinolones: High resistance (72-93%) and pregnancy concerns 7, 5
• Cephalosporins: Complete resistance in ESBL-producers 6
• Trimethoprim-sulfamethoxazole: High resistance rates 9

Duration of Treatment

Follow standard UTI duration based on clinical syndrome, NOT extended for ESBL 10:

• Cystitis: 3-5 days (depending on agent used)
• Pyelonephritis: 7-14 days total
• Bacteremia from urinary source: 7 days total when source control achieved 10

The 2024 JAMA guidelines explicitly state that multidrug-resistant organisms do not require longer treatment durations than non-resistant organisms, provided the antimicrobial demonstrates activity and appropriate source control is obtained 10.

Critical Risk Factors to Document

This patient likely has ESBL due to:

• Recent hospitalization (within 3 months) 4
• Prior antimicrobial exposure (within 3 months) 4
• Previous UTI (within 6 months) 4
• Known MDRO carriage history (within 2 years) 4

Stewardship Considerations

De-escalation strategy 10:

• Start with carbapenem empirically if ESBL suspected
• Transition to oral fosfomycin or nitrofurantoin once clinically stable and susceptibilities confirm activity
• Multiple RCTs demonstrate all-oral or mostly-oral regimens achieve comparable outcomes with reduced hospital stay 10

Key Pitfalls to Avoid

1. Do not extend treatment duration simply because organism is ESBL-producing 10
2. Do not use amoxicillin-clavulanate even if in vitro susceptible—clinical outcomes are poor 4
3. Screen for cardiac risk before using IV fosfomycin 1
4. Limit aminoglycoside duration to prevent nephrotoxicity 1
5. Obtain susceptibilities before assuming empiric coverage is adequate—local resistance patterns vary significantly 9, 7

The ESBL prevalence in pregnant women ranges 16-44% in recent studies 9, 3, 7, making culture-directed therapy essential rather than prolonged empiric broad-spectrum treatment.